ストックスクリーナーアプリを入手
88.46
0.07%
0.06
アフターアワーズ：
88.41
-0.05
-0.06%
前日終値:
$88.40
開ける：
$88.385
24時間の取引高:
8.70M
Relative Volume:
1.42
時価総額：
$110.24B
収益：
$28.30B
当期純損益:
$126.00M
株価収益率:
20.34
EPS:
4.35
ネットキャッシュフロー:
$9.43B
1週間 パフォーマンス:
-8.83%
1か月 パフォーマンス:
+2.01%
6か月 パフォーマンス:
+30.63%
1年 パフォーマンス:
+17.24%
1日の値動き範囲:
$87.63
$89.04
1週間の範囲:
$87.63
$96.84
52週間の値動き範囲:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| GILD | 88.46 | 110.24B | 28.30B | 126.00M | 9.43B | 4.35 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead announces impending layoffs, facility closure - LabPulse
26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma
Gilead’s Livdelzi shows promise in PBC clinical trial - Clinical Trials Arena
Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India
5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat
CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times
Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com
Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE
Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance
Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - StreetInsider.com
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - Business Wire
Empowered Funds LLC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
As an HIV+ activist, I know drug companies aren't doing enough to end AIDS - Yahoo News UK
Dearborn Partners LLC Has $26.76 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLC - MarketBeat
Citigroup Upgrades Gilead Sciences (NASDAQ:GILD) to Strong-Buy - MarketBeat
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites - BioSpace
Gilead Sciences to close Seattle office; shutdown impacts 72 employees - MSN
COVID drugmaker to close Seattle office, lay off 72 workers - The Seattle Times
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics - Barchart
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site - Fierce Biotech
ING Groep NV Acquires 109,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences to Close Seattle Office, Lay Off 72 Employees Located at Alexandria’s 199 E. Blaine Property - The Registry Seattle
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by KBC Group NV - MarketBeat
Gilead Sciences (NASDAQ:GILD) Coverage Initiated by Analysts at Citigroup - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bell Bank - MarketBeat
Prime Capital Investment Advisors LLC Sells 14,908 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Prices $3.5 Billion of Senior Unsecured Notes - BioSpace
Biotech giant Gilead Sciences to close its Seattle office, lay off employees - The Business Journals
Gilead Sciences Raises $3.5B in Multi-Tranche Notes Offering with 40-Year Terms | GILD Stock News - StockTitan
Gilead data lends insight into transforming HIV prevention landscape - European Pharmaceutical Review
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.03%
1.71%
大文字化:
|
ボリューム (24 時間):